Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including ...

Frank Laukien, President and CEO, reported that Bruker achieved Q4 2024 constant exchange rate (CER) revenue growth of 15.8%, with reported revenues reaching $979.6 million and organic growth of 3.9%.

“I look forward to contributing to Bruker’s continued innovation and growth in the life sciences and diagnostics industries.” Frank H. Laukien, chairman, president and CEO of Bruker ...

My name is Joe Kostka, and I'm the Director of Bruker Investor Relations. Joining me on today's call are Frank Laukien, our President and CEO; and Gerald Herman, our EVP and CFO. In addition to ...

Bruker Corp (NASDAQ:BRKR ... Is it ELITech, AI, aftermarket service, or European offsets? A: Frank Laukien, CEO: There are multiple growth drivers outside the U.S., including biopharma recovery ...

Bruker Corporation (NASDAQ ... On a positive note, the CEO purchased shares on weakness, which helped boost sentiment. While we acknowledge the near-term uncertainty around the stock due to ...